Zinc Status in Children and Young Adults With Sickle Cell Disease

Abshire, Thomas C.; English, J. L.; Githens, John H.; Hambidge, K. Michael

doi:10.1001/archpedi.1988.02150120110052

Cited by 4 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This lack of many similar features, but each of them has peculiar redox change renders it stable in a biological medium advantages and disadvantages depending on the appliwhose oxidoreductive potential is subject to continual flux. Other physicochemical qualities that provide important advantages to biological systems include the TABLE 1. Detection limits j&r zinc in biological matter fact that it is amphoteric, existing both as the aquo and of various analytic techniques hydroxo metal complex at pH values near neutrality.…”

Section: B Spectroscopymentioning

confidence: 99%

“…It is not clear whether the reductions in zinc are due to its uptake by the liver owing either to effects of acute-phase hormones, cytokines, increased excretion in the urine, or all of these, as is observed in a chronic illness such as cirrhosis or in acute disorders such as trauma and burns (100,109,309,515); nor is it certain that the decrease occurs in all patients affected by each of these disorders. In some sickle cell patients, for example, the plasma zinc content remains normal (1). mainder is bound to other enzymes and proteins (384).…”

Section: Hematologymentioning

confidence: 99%

See 1 more Smart Citation

The biochemical basis of zinc physiology

Vallée

Falchuk²

1993

Physiological Reviews

2,635

2,002

View full text Add to dashboard Cite

Section: B Spectroscopymentioning

confidence: 99%

Section: Hematologymentioning

confidence: 99%

The biochemical basis of zinc physiology

Vallée

Falchuk²

1993

Physiological Reviews

2,635

2,002

View full text Add to dashboard Cite

“…A total of 36 studies published from 1974 to 2019 met the eligibility criteria and were further included for evidence synthesis; 15 from Africa, 9 from the United States, 8 from Asia, and 4 from Europe. 8 9 12 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Details of the selection process are summarized in ( Fig. 1 ).…”

Section: Resultsmentioning

confidence: 99%

Zinc, Magnesium, and Copper Levels in Patients with Sickle Cell Disease: A Systematic Review and Meta-analysis

Elkhidir

Ali

et al. 2022

Avicenna J Med

View full text Add to dashboard Cite

Background Sickle cell disease (SCD) is associated with oxidative stress due to an imbalance between production and elimination of the reactive oxygen species. It has been reported that SCD patients are at risk of multiple micronutrients' deficiencies, including several trace elements involved in the antioxidation mechanisms. We aimed to assess the status of these micronutrients in SCD patients. Methods This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The databases of MedLine, Embase, and PsycInfo were used for the systematic search from time the databases existed until April 2021. A total of 36 studies fulfilled the eligibility criteria. We calculated the pooled standardized mean difference (SMD) of serum zinc, magnesium, or copper levels among patients with SCD and their healthy controls. Results SCD patients had significantly lower zinc (SMD = −1.27 [95% CI: 1.67−0.87, p 0.001]) and magnesium levels (SMD = −0.53 [95% CI: 1.0−0.06, p 0.026] than their controls. Copper level was found to be significantly higher in SCD patients, with SMD = 0.68 (95% CI: 0.05−1.32, p 0.004). Conclusion This review showed that SCD patients may potentially prompt to have lower zinc and magnesium levels and higher copper levels compared with those without the disease. Future research need to be directed to investigate clinical outcome of nutritional difficiencies in patients with SCD, as well as the possibility of implementing nutritional supplement programs which may help minimizing the harmful effects of the disease on human body.

show abstract

“…There is widespread evidence of zinc deficiency in the context of SCA with studies showing urinary zinc loss in SCA [16] rather than dietary deficiency [17]. This is supported by global data showing reduced zinc levels or zinc deficiency in 15/18 studies in children or adults with SCA, including studies from North America (USA, Canada), South America (Brazil), the Middle East (Saudi Arabia, Turkey, Iraq, Jordan), and Africa (Nigeria, Uganda) [16,[18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34]. Subsequent studies have shown that urinary zinc loss is likely due to impaired renal tubular reabsorption of zinc [35], presumably due to tubular damage from SCA, and that bone degradation, particularly during painful VOC, may lead to increased release of zinc and subsequent loss in the urine, resulting in further depletion of body zinc levels [36].…”

Section: Introductionmentioning

confidence: 89%

Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS): Study Protocol for a Randomized Placebo-Controlled Trial in Ugandan children with Sickle Cell Anemia

Datta

Namazzi

Conroy

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Sickle cell anemia (SCA) is the most common inherited hemoglobinopathy worldwide. Infection is a major cause of illness and death in children with SCA, especially in sub-Saharan Africa where an estimated 50-90% of affected children die before their fifth birthday. Interventions to reduce the incidence and severity of infections are needed urgently. A high proportion of adults and children with SCA are zinc-deficient, and zinc deficiency leads to impaired immunity and an increased risk of infection. Zinc supplementation has been shown to decrease the risk of infection in adolescents and adults, but there are no data on the effectiveness of zinc for prevention of infection in children < 5 years of age with SCA. Methods/design: The study will be a randomized, placebo-controlled, double-blind clinical trial in which 250 Ugandan children 1.00-4.99 years of age with SCA will receive daily zinc supplementation (10 mg oral dispersible tablet) or identical placebo for 12 months.Discussion: If this trial shows a reduction in severe or invasive infection incidence, it would be the basis for a multisite, multi-country clinical trial to assess real-world safety and efficacy of zinc in African children with SCA. Since zinc is safe, inexpensive, and easy to administer, this trial has the potential to improve the health of hundreds of thousands of African children with SCA through reduction of infection-related morbidity and mortality.

show abstract

Zinc Status in Children and Young Adults With Sickle Cell Disease

Cited by 4 publications

References 21 publications

The biochemical basis of zinc physiology

The biochemical basis of zinc physiology

Zinc, Magnesium, and Copper Levels in Patients with Sickle Cell Disease: A Systematic Review and Meta-analysis

Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS): Study Protocol for a Randomized Placebo-Controlled Trial in Ugandan children with Sickle Cell Anemia

Contact Info

Product

Resources

About